1. Tofacitinib as induction and maintenance therapy for ulcerative colitis;Sandborn;N Engl J Med,2017
2. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis;Hanauer;Clin Gastroenterol Hepatol,2019
3. US Food and Drug Administration, Xeljanz® (tofacitinib): highlights of prescribing information. 2021. https://labeling.pfizer.com/showlabeling.aspx?id=959. Accessed June 18, 2023.
4. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis;Ytterberg;N Engl J Med,2022
5. US Food and Drug Administration, Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients. FDA to investigate. 2019 https://www.fda.gov/media/120485/download Accessed June 8, 2023.